Everything below concerns Peptidomimetic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-24. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
When Burger King Corporation began franchising in 1959, it used a regional model where franchisees purchased the right to open stores within a geographic region. These franchise agreements granted BKC very little oversight control of its franchisees and resulted in issues of product quality control, store image and design, and operational procedures. During the 1970s, structural deficiencies in Burger King's franchise system became increasingly problematic for Pillsbury. A major example was the relationship between Burger King and Louisiana-based franchisee Chart House, Burger King's largest franchisee group at the time with over 350 locations in the United States. The company's owners, William and James Trotter, made several moves to take over or acquire Burger King during the 1970s, all of which were spurned by Pillsbury. After the failed attempts to acquire the company, the relationship between Chart House and Burger King soured and eventually devolved into a lawsuit. Chart House eventually spun off its Burger King operations in the early 1980s into a holding company called DiversiFoods which, in turn, was acquired by Pillsbury in 1984 and absorbed into Burger King's operations. As part of the franchising reorganization segment of Operation Phoenix, Donald N. Smith initiated a restructuring of future franchising agreements in 1978.
== Mechanism == Smooth muscle cells make up the involuntary muscles, which are found in most parts of the body, including the uterus, stomach and intestines, the walls of all blood vessels, and the skin. These are the areas where LMSs originate. LMSs also often develop in the retroperitoneal region which consists of the suprarenal glands, the kidney, and ureter. Just as it is not known what truly causes most sarcomas, LMSs have similarly complex karyotypes and it is suggested that because of the complexity, genomic instability might be the cause. Uterine leiomyosarcomas come from the smooth muscle in the muscle layer of the uterus. Cutaneous leiomyosarcomas derive from the pilo-erector muscles in the skin. Gastrointestinal leiomyosarcomas might come from smooth muscle in the gastrointestinal (GI) tract, or alternatively, from a blood vessel. At most other primary sites—retroperitoneal extremity (in the abdomen, behind the intestines), truncal, abdominal organs, etc.—leiomyosarcomas appear to grow from the muscle layer of a blood vessel (the tunica media). Thus, a leiomyosarcoma can have a primary site of origin anywhere in the body from a blood vessel. The tumors are usually hemorrhagic, soft, and microscopically marked by pleomorphism, abundant (15–30 per 10 high-power fields) abnormal mitotic figures, and coagulative tumor cell necrosis. The differential diagnosis, which includes spindle cell carcinoma, spindle cell melanoma, fibrosarcoma, malignant peripheral nerve sheath tumor, and even biphenotypic sinonasal sarcoma, is wide.
== History == Dexamethasone was first synthesized by Philip Showalter Hench in 1957. It was introduced for medical use in 1958. On 16 June 2020, the RECOVERY Trial announced preliminary results stating that dexamethasone improves survival rates of hospitalized patients with COVID-19 receiving oxygen or on a ventilator. Benefits were only observed in patients requiring respiratory support; those who did not require breathing support saw a worse survival rate than the control group, although the difference may have been due to chance. A preprint containing the full dataset was published on 22 June 2020, and demand for dexamethasone surged after the publication of the preprint. The preliminary report was published in The New England Journal of Medicine on 18 July 2020. The final report was published in February 2021. The World Health Organization (WHO) states that dexamethasone should be reserved for seriously ill and critical patients receiving COVID-19 treatment in a hospital setting, and the WHO Director-General stated that "WHO emphasizes that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision. There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm." In July 2020, the WHO stated they were in the process of updating treatment guidelines to include dexamethasone or other steroids. In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19.
Charles Miller Metzner (1931), judge on the United States District Court for the Southern District of New York and the Temporary Emergency Court of Appeals Lawrence E. Walsh (1932), independent counsel in the Iran-Contra affair; 4th United States Deputy Attorney General William Golub (1934), lawyer and advisor to Governor Nelson Rockefeller Harold Leventhal (1934), judge on the United States Court of Appeals for the District of Columbia Circuit John Slate (1935), lawyer and name partner of Skadden Arps Slate Meagher & Flom Daniel Mortimer Friedman (1937), judge of the United States Court of Appeals for the Federal Circuit, last chief judge of the United States Court of Claims, and acting solicitor general of the United States Wilfred Feinberg (1940), judge of the United States Court of Appeals for the Second Circuit Hugh H. Bownes (1941), judge of the United States Court of Appeals for the First Circuit Richard Kuh (1941), New York County district attorney and prosecutor of Lenny Bruce for obscenity Leonard I. Garth (1942), senior judge on the United States Court of Appeals for the Third Circuit Charles L. Brieant (1944), judge of the United States District Court for the Southern District of New York Jack Greenberg (1945), civil rights lawyer who argued the Brown v. Board of Education case before the United States Supreme Court Roy Cohn (1946), attorney and counsel to Sen. Joseph McCarthy Arthur Lazarus Jr. (1947), American Indian rights lawyer, argued United States v.
Sources: en.wikipedia.org
=== Vaccine development and advance market commitments === Advance Market Commitments (AMCs) aim to overcome market failure by making an advance pledge that if a vaccine for a certain condition is developed, meeting certain specifications, donors will buy a certain number of doses. Gavi seeks to design its AMCs in a way that encourages a competitive market. Gavi has been particularly successful at promoting the uptake of newer vaccines.
Derek Thompson of The Atlantic argued that DiCaprio gives his best performances when playing "frauds and cheats and double-crossing liars and mercenaries". Several media publications, such as People, Empire and Harper's Bazaar, have included DiCaprio in their listings of the most attractive actors. In 1998, he sued Playgirl magazine over plans to publish a fully nude picture of him. He has said he does not believe in focusing on appearance—as this is only temporary and can negatively affect one's profession in the industry—and looks for career longevity instead. In 2005, DiCaprio was made a commander of the Ordre des Arts et des Lettres by the French Minister of Culture for his contributions to the arts. In 2016, he was named one of the 100 most influential people in the world by Time magazine. He was included on Forbes' annual list of the world's highest-paid actors in 2008 and from 2010 to 2016 with respective earnings of $45 million, $28 million, $77 million, $37 million, $39 million, $39 million, $29 million and $27 million, topping the list in 2011. The magazine has commended DiCaprio's ability to star in risky, R-rated films that become box office successes. The Hollywood Reporter listed him as one of the 100 most powerful people in entertainment from 2016 to 2019. A writer for the same magazine credits DiCaprio as the rare actor to have a successful career "without ever having made a comic book movie, family film or pre-branded franchise.
Traceability: The ability to reconstruct the development history of a drug or medical device. Accountability: The ability to resolve who has contributed what to the development and when. Another version, ALCOA++, adds:
Sources: en.wikipedia.org
== Presence in nonerythroid cells == Some nonerythroid cells (i.e., cells other than the red blood cell line) contain hemoglobin. In the brain, these include the A9 dopaminergic neurons in the substantia nigra, astrocytes in the cerebral cortex and hippocampus, and in all mature oligodendrocytes. It has been suggested that brain hemoglobin in these cells may enable the "storage of oxygen to provide a homeostatic mechanism in anoxic conditions, which is especially important for A9 DA neurons that have an elevated metabolism with a high requirement for energy production". It has been noted further that "A9 dopaminergic neurons may be at particular risk of anoxic degeneration since in addition to their high mitochondrial activity they are under intense oxidative stress caused by the production of hydrogen peroxide via autoxidation and/or monoamine oxidase (MAO)-mediated deamination of dopamine and the subsequent reaction of accessible ferrous iron to generate highly toxic hydroxyl radicals". This may explain the risk of degeneration of these cells in Parkinson's disease. The hemoglobin-derived iron in these cells is not the cause of the post-mortem darkness of these cells (origin of the Latin name, substantia nigra), but rather is due to neuromelanin. Outside the brain, hemoglobin has non-oxygen-carrying functions as an antioxidant and a regulator of iron metabolism in macrophages, alveolar cells, and mesangial cells in the kidney.
Jerden later said that he was told Staley felt animosity toward him dating back to the Dirt sessions due to Jerden repeatedly recommending to Staley that he get sober. Jerden said, "Apparently he got all mad at me [during the Dirt sessions] ... And what's my job as a producer? To produce a record. I'm not getting paid to be Layne's friend". Staley was not the only one who went through heavy drug use; drummer Sean Kinney and bassist Mike Starr were both struggling with alcoholism, while the latter was also addicted to heroin. Jerden got the album's famous guitar tone by blending three different amps – a Bogner Fish preamp for the low end, a Bogner Ecstacy for the mid frequencies, and a Rockman Headphone amp for the high frequencies.
=== Material Science Applications === Organic Electronics Polymeric Materials Consumer Packaged Goods Catalysis & Reactivity Thin Film Processing Energy Capture & Storage Pharmaceutical Formulations & Delivery Metals, Alloys & Ceramics In addition to computational platforms, Schrödinger develops custom software for enterprises, as well as training, computer-cluster design and implementation, and research-based drug discovery projects. Schrödinger software licenses are available to academic institutions for education and not-for-profit research.
Rutherford deduced the existence of the atomic nucleus through his experiments but he had nothing to say about how the electrons were arranged around it. In 1912, Niels Bohr joined Rutherford's lab and began his work on a quantum model of the atom. Max Planck in 1900 and Albert Einstein in 1905 had postulated that light energy is emitted or absorbed in discrete amounts known as quanta (singular, quantum). This led to a series of atomic models with some quantum aspects, such as that of Arthur Erich Haas in 1910 and the 1912 John William Nicholson atomic model with quantized angular momentum as h/2π. Critically, Nicholson successfully reproduces atomic spectral lines, a challenge that Bohr's model would also need to overcome. When Bohr learned from a friend about Balmer's compact formula for the spectral line data, Bohr quickly realized his model would match it in detail. In 1913, Bohr published a trilogy of papers developing his model of the atom based on two hypothesis: 1) an electron could change states only by "quantum leaps" and 2) the jump corresponds to a emission of light according to Planck relation. With these assumptions, the instability of the older models becomes irrelevant and the classical electrodynamics of Maxwell is considered invalid. Using circular orbits for simplicity, Bohr could then derived Balmer's spectral formula. Balmer's formula contained a constant now known as the Rydberg constant with a value known only by matching experimental results.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.